What United States law permits for each peptide today: an FDA-approved product, compounding by a licensed 503A pharmacy, or no lawful route at all. Every status carries the date it was last verified, because the ground moved twice in 2026.
40 molecules · statuses verified September 2026
| Molecule | Class | US status | Position |
|---|---|---|---|
| TesamorelinEGRIFTA; GHRH(1–44) analogue | GH secretagogues | FDA-approved | Approved since 2010; EGRIFTA WR (weekly reconstitution) approved March 2025. Verified August 2026. |
| BPC-157Body Protection Compound 157; pentadecapeptide BPC | Repair peptides | PCAC-recommended · pending | Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026. |
| SemaglutideOzempic; Wegovy; Rybelsus | GLP-1 receptor agonists | FDA-approved | Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains. Verified August 2026. |
| TirzepatideMounjaro; Zepbound | GLP-1 receptor agonists | FDA-approved | Approved brand products; shortage resolved October 2024; same narrow 503A posture as semaglutide. Verified August 2026. |
| SermorelinGHRH(1–29); formerly Geref | GH secretagogues | Compoundable (503A) | Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A. Verified August 2026. |
| NAD+Nicotinamide adenine dinucleotide | Mitochondrial | Compoundable (503A) | Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates. Verified August 2026. |
| Glutathione | Mitochondrial | Compoundable (503A) | Category 1 of the interim 503A bulks list; compoundable with a valid prescription. Verified August 2026. |
| CJC-1295 | GH secretagogues | Nomination withdrawn | Removed from Category 2 in September 2024 after its nominators withdrew; on no list; no lawful compounding route. Verified August 2026. |
| Ipamorelin | GH secretagogues | Nomination withdrawn | 503A nominations withdrawn September 2024 and in no 503A category; named in Category 2 under FDA's separate 503B policy; no lawful compounding route. |
| GHK-CuCopper tripeptide-1 | Repair peptides | Compoundable (503A) | Nominations withdrawn April 2026; the non-injectable route was restored to Category 1 in May, the injectable route was not and has no lawful route. Verified August 2026. |
| MOTS-c | Mitochondrial | PCAC-recommended · pending | Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026. |
| TB-500Thymosin beta-4 fragment | Repair peptides | PCAC-recommended · pending | Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026. |
| KPVLysine-proline-valine; alpha-MSH fragment | Repair peptides | PCAC-recommended · pending | Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026. |
| Semax | Neuropeptides | PCAC-recommended · pending | Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026. |
| EpitalonEpithalon; AEDG tetrapeptide | Longevity peptides | PCAC-recommended · pending | Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026. |
| DSIPDelta sleep-inducing peptide; emideltide | Neuropeptides | No lawful route | Removed from Category 2 in April 2026; the only peptide PCAC declined to recommend at the July 2026 meeting; no lawful route. Verified August 2026. |
| Melanotan IIMelanotan-2; MT-II | Melanocortins | No lawful route | Nomination withdrawn in 2026; on no list. FDA's published safety finding — melanoma, priapism, and two acute toxicity syndromes in case reports — was never retracted. Verified August 2026. |
| LL-37Cathelicidin LL-37; hCAP18 | Immune peptides | No lawful route | Nomination withdrawn in 2026; on no list. FDA's safety finding cites nonclinical evidence of harm to male reproduction and of pro-tumorigenic effects in some tissues. Verified August 2026. |
| DihexaDihexa acetate; PNB-0408 | Neuropeptides | No lawful route | Nomination withdrawn in 2026; on no list. FDA states it has identified no human exposure data for this substance by any route. Verified August 2026. |
| CerebrolysinPeptide fraction derived from porcine brain protein; FPF-1070 | Neuropeptides | No lawful route | Licensed in Austria, never approved in the US; FDA stated in 2020 and 2021 warning letters that it had not been nominated for the 503A bulks list, and no list names it. |
| PEG-MGFMechano growth factor pegylated; IGF-1Ec | Growth factor fragments | No lawful route | Nomination withdrawn in 2026; on no list. The unpegylated parent, mechano growth factor, sits in Category 3 — nominated without adequate support. Verified August 2026. |
| AOD-9604hGH fragment 176-191 | Growth factor fragments | Nomination withdrawn | The advisory committee voted 0–12 against listing it in December 2024; the nomination was later withdrawn. On no list, and no lawful compounding route. Verified August 2026. |
| Thymosin alpha-1Thymalfasin; Ta1 | Immune peptides | Nomination withdrawn | Licensed as a medicine in other countries and never approved here; the advisory committee voted 4–17 against listing it in December 2024, and the nomination was withdrawn. Verified August 2026. |
| Kisspeptin-10KP-10; metastin(45–54) | Neuropeptides | No lawful route | The only peptide FDA still lists in Category 2 of the 503A bulks list; placed there September 2023, and the advisory committee voted 0–11 against listing it in October 2024. Verified August 2026. |
| SelankSelank acetate; TP-7 | Neuropeptides | Nomination withdrawn | Nomination withdrawn; on no list, and never placed on an advisory-committee agenda — the disposition with the least record behind it. Verified August 2026. |
| SetmelanotideRM-493; Imcivree | Melanocortins | FDA-approved | Approved November 2020 as Imcivree for rare genetic and acquired hypothalamic obesity; the label states it is not indicated for general obesity. |
| PT-141Bremelanotide; Vyleesi | Melanocortins | FDA-approved | Approved June 2019 as Vyleesi for one narrowly defined indication in premenopausal women; the label states it is not indicated for men. Verified August 2026. |
| LiraglutideVictoza; Saxenda | GLP-1 receptor agonists | FDA-approved | Approved since 2010, generic since 2024, and still listed as in shortage — the only molecule in this index whose supply problem is unresolved. Verified August 2026. |
| RetatrutideLY3437943 | GLP-1 receptor agonists | No lawful route | Investigational and unapproved; FDA states plainly that it cannot be used in compounding under federal law, and has issued warning letters over research-use-only sales. Verified August 2026. |
| GHRP-2Growth hormone releasing peptide-2; pralmorelin | GH secretagogues | No lawful route | Category 3 of the 503A bulks list — nominated without adequate support — and Category 2 under the separate 503B policy for injectable and nasal routes; no lawful route. |
| GHRP-6Growth hormone releasing peptide-6; growth hormone releasing hexapeptide | GH secretagogues | No lawful route | Category 3 of the 503A bulks list — nominated without adequate support — and Category 2 under the separate 503B policy; no lawful route. |
| Mechano growth factorMGF; IGF-1Ec | Growth factor fragments | No lawful route | Category 3 of the 503A bulks list — nominated without adequate support. The pegylated form sits in no category at all, its nomination withdrawn. |
| ARA-290Cibinetide; helix B surface peptide | Repair peptides | No lawful route | Category 3 of the 503A bulks list — nominated without adequate support — despite five indexed human trials, which is the distance between a literature and a nomination. |
| Vasoactive intestinal peptideVIP; aviptadil | Gut peptides | Compoundable (503A) | Category 1 of the interim 503A bulks list; a pharmacy may compound it while FDA review continues. No approved product containing it exists. |
| SecretinSynthetic human secretin; ChiRhoStim | Gut peptides | FDA-approved | An approved diagnostic drug since 2004, and separately a bulk substance nominated to the 503A list without adequate support; the nomination sits in Category 3. |
| ThymulinThymulin acetate; serum thymic factor | Immune peptides | No lawful route | Category 3 of the 503A bulks list — nominated without adequate support; no approved product and no lawful compounding route. |
| L-carnosineCarnosine; beta-alanyl-L-histidine | Longevity peptides | No lawful route | Category 3 of the 503A bulks list — nominated without adequate support — despite a large randomized literature, almost all of it oral supplementation. |
| ElamipretideSS-31; MTP-131; Forzinity | Mitochondrial | FDA-approved | Approved September 2025 as Forzinity under accelerated approval for Barth syndrome; the only approved product in this index's mitochondrial group. |
| AfamelanotideMelanotan-I; Scenesse; CUV1647 | Melanocortins | FDA-approved | Approved October 2019 as Scenesse for one rare photodermatosis; the pre-approval literature calls the same compound melanotan-I. |
| DulaglutideTrulicity; LY2189265 | GLP-1 receptor agonists | FDA-approved | Licensed September 2014 as Trulicity for type 2 diabetes and cardiovascular risk; the current label carries no weight-management indication. |
EGRIFTA; GHRH(1–44) analogue
Approved since 2010; EGRIFTA WR (weekly reconstitution) approved March 2025. Verified August 2026.
Body Protection Compound 157; pentadecapeptide BPC
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026.
Ozempic; Wegovy; Rybelsus
Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains. Verified August 2026.
Mounjaro; Zepbound
Approved brand products; shortage resolved October 2024; same narrow 503A posture as semaglutide. Verified August 2026.
GHRH(1–29); formerly Geref
Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A. Verified August 2026.
Nicotinamide adenine dinucleotide
Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates. Verified August 2026.
Category 1 of the interim 503A bulks list; compoundable with a valid prescription. Verified August 2026.
Removed from Category 2 in September 2024 after its nominators withdrew; on no list; no lawful compounding route. Verified August 2026.
503A nominations withdrawn September 2024 and in no 503A category; named in Category 2 under FDA's separate 503B policy; no lawful compounding route.
Copper tripeptide-1
Nominations withdrawn April 2026; the non-injectable route was restored to Category 1 in May, the injectable route was not and has no lawful route. Verified August 2026.
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026.
Thymosin beta-4 fragment
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026.
Lysine-proline-valine; alpha-MSH fragment
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026.
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026.
Epithalon; AEDG tetrapeptide
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule. Verified August 2026.
Delta sleep-inducing peptide; emideltide
Removed from Category 2 in April 2026; the only peptide PCAC declined to recommend at the July 2026 meeting; no lawful route. Verified August 2026.
Melanotan-2; MT-II
Nomination withdrawn in 2026; on no list. FDA's published safety finding — melanoma, priapism, and two acute toxicity syndromes in case reports — was never retracted. Verified August 2026.
Cathelicidin LL-37; hCAP18
Nomination withdrawn in 2026; on no list. FDA's safety finding cites nonclinical evidence of harm to male reproduction and of pro-tumorigenic effects in some tissues. Verified August 2026.
Dihexa acetate; PNB-0408
Nomination withdrawn in 2026; on no list. FDA states it has identified no human exposure data for this substance by any route. Verified August 2026.
Peptide fraction derived from porcine brain protein; FPF-1070
Licensed in Austria, never approved in the US; FDA stated in 2020 and 2021 warning letters that it had not been nominated for the 503A bulks list, and no list names it.
Mechano growth factor pegylated; IGF-1Ec
Nomination withdrawn in 2026; on no list. The unpegylated parent, mechano growth factor, sits in Category 3 — nominated without adequate support. Verified August 2026.
hGH fragment 176-191
The advisory committee voted 0–12 against listing it in December 2024; the nomination was later withdrawn. On no list, and no lawful compounding route. Verified August 2026.
Thymalfasin; Ta1
Licensed as a medicine in other countries and never approved here; the advisory committee voted 4–17 against listing it in December 2024, and the nomination was withdrawn. Verified August 2026.
KP-10; metastin(45–54)
The only peptide FDA still lists in Category 2 of the 503A bulks list; placed there September 2023, and the advisory committee voted 0–11 against listing it in October 2024. Verified August 2026.
Selank acetate; TP-7
Nomination withdrawn; on no list, and never placed on an advisory-committee agenda — the disposition with the least record behind it. Verified August 2026.
RM-493; Imcivree
Approved November 2020 as Imcivree for rare genetic and acquired hypothalamic obesity; the label states it is not indicated for general obesity.
Bremelanotide; Vyleesi
Approved June 2019 as Vyleesi for one narrowly defined indication in premenopausal women; the label states it is not indicated for men. Verified August 2026.
Victoza; Saxenda
Approved since 2010, generic since 2024, and still listed as in shortage — the only molecule in this index whose supply problem is unresolved. Verified August 2026.
LY3437943
Investigational and unapproved; FDA states plainly that it cannot be used in compounding under federal law, and has issued warning letters over research-use-only sales. Verified August 2026.
Growth hormone releasing peptide-2; pralmorelin
Category 3 of the 503A bulks list — nominated without adequate support — and Category 2 under the separate 503B policy for injectable and nasal routes; no lawful route.
Growth hormone releasing peptide-6; growth hormone releasing hexapeptide
Category 3 of the 503A bulks list — nominated without adequate support — and Category 2 under the separate 503B policy; no lawful route.
MGF; IGF-1Ec
Category 3 of the 503A bulks list — nominated without adequate support. The pegylated form sits in no category at all, its nomination withdrawn.
Cibinetide; helix B surface peptide
Category 3 of the 503A bulks list — nominated without adequate support — despite five indexed human trials, which is the distance between a literature and a nomination.
VIP; aviptadil
Category 1 of the interim 503A bulks list; a pharmacy may compound it while FDA review continues. No approved product containing it exists.
Synthetic human secretin; ChiRhoStim
An approved diagnostic drug since 2004, and separately a bulk substance nominated to the 503A list without adequate support; the nomination sits in Category 3.
Thymulin acetate; serum thymic factor
Category 3 of the 503A bulks list — nominated without adequate support; no approved product and no lawful compounding route.
Carnosine; beta-alanyl-L-histidine
Category 3 of the 503A bulks list — nominated without adequate support — despite a large randomized literature, almost all of it oral supplementation.
SS-31; MTP-131; Forzinity
Approved September 2025 as Forzinity under accelerated approval for Barth syndrome; the only approved product in this index's mitochondrial group.
Melanotan-I; Scenesse; CUV1647
Approved October 2019 as Scenesse for one rare photodermatosis; the pre-approval literature calls the same compound melanotan-I.
Trulicity; LY2189265
Licensed September 2014 as Trulicity for type 2 diabetes and cardiovascular risk; the current label carries no weight-management indication.
Each row above links a monograph carrying that molecule’s dated regulatory ledger, and each posture is defined in the glossary. The record is also published as tables, the 2026 chronology and the July 2026 vote ledger among them:
Evidence reviews — measured answers to the questions this index is asked most — are collected on the evidence hub.